PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule

Composition of matter patent covers the Company’s novel PGN-EDODM1 molecule and serves as a cornerstone of its expanding patent portfolio BOSTON --(BUSINESS WIRE)--Nov. 12, 2025-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide